TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company's lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. It also engages in developing Cx611, a clinical stage product candidate from its expanded adipose-derived stem cell-based (eASC-based) technology platform, which completed a Phase I study in sepsis and a Phase I/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It is also developing AlloCSC-01, a product candidate based on the CSC-based platform, which is in the second stage of a European Phase I/II trial in acute myocardial infarction; and AlloCSC-02 that is in a preclinical proof of concept stage for a chronic cardiac indication. The company has operations primarily in Belgium, Spain, and the United States. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium.

1.77 EUR
As of 05/09/2018

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  03/22/2007
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   Belgium
Market cap:   546,960,064 EUR
Current dividend yield:   0.00%
Sedol:      B1VJVX2

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy